Prostate cancer screening often detects indolent cancers—defined as those which would never cause morbidity or mortality if left undetected and untreated. Unnecessary treatment of indolent cancer is a problem associated with this 'overdetection'. Active surveillance is a management strategy for low-risk cancers which can decrease the overtreatment burden.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Andriole, G. L. et al. Mortality results from a randomized prostate cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).
Hugosson, J. et al. Mortality results from the Göteborg randomised population-based prostate cancer screening trial. Lancet Oncol. 11, 725–732 (2010).
Carroll, P. R., Whitson, J. M. & Cooperberg, M. R. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J. Clin. Oncol. doi:10.1200/JCO.2010.32.5308.
Loeb, S. et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J. Clin. Oncol. doi:10.1200/JCO.2010.30.6373.
Dall'Era, M. A. et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112, 2664–2670 (2008).
Klotz, L. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28, 126–131 (2010).
Hayes, J. H. et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304, 2373–2380 (2010).
Cooperberg, M. R. et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J. Clin. Oncol. 29, 228–234 (2011).
Fleshner, N. et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp. Clin. Trials 28, 763–769 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. R. Carroll declares that he acts as a consultant for Steba Biotech and Myriad Pharmaceuticals, has received Speaker's Bureau honararia from Takeda Pharmaceuticals and receives grant support from Abbott Laboratories. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Whitson, J., Porten, S. & Carroll, P. Reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol 8, 124–125 (2011). https://doi.org/10.1038/nrurol.2011.8
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.8
This article is cited by
-
Diagnostische Histopathologie des Prostatakarzinoms
Der Urologe (2013)
-
Die Bedeutung der Pathologie in der deutschen Prostatakrebsstudie PREFERE
Der Pathologe (2013)